Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study

(2023) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics

(2023) Vivek Purohit et al.   AAPS Journal

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

(2023) Brett King et al.   LANCET

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis

(2022) Jessica Wojciechowski et al.   CLINICAL PHARMACOKINETICS

Efficient and relevant stepwise covariate model building for pharmacometrics

(2022) Robin J. Svensson et al.   CPT-Pharmacometrics & Systems Pharmacology

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial

(2022) Khaled Ezzedine et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

(2021) Brett King et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers

(2021) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor in Patients with Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2020) Michael F. Robinson et al.   Arthritis & Rheumatology

Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine

(2020) Anna H.-X. P. Chan Kwong et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

PF-06651600, a dual JAK3/TEC family kinase inhibitor

(2019) Hua Xu et al.   ACS Chemical Biology

Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials

(2019) Ahmed Nader et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Pharmacokinetics in Kidney Disease

(2018) Tom N. Lea-Henry et al.   Clinical Journal of the American Society of Nephrology

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition

(2016) Jean-Baptiste Telliez et al.   ACS Chemical Biology

A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD

(2015) Thomas D. Nolin   SEMINARS IN DIALYSIS

A Quantitative Approach to Drug Dosing in Chronic Kidney Disease

(2011) Ali J. Olyaei et al.   BLOOD PURIFICATION

Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis

(2011) C Schmitt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Modeling the Autoinhibition of Clarithromycin Metabolism during Repeated Oral Administration

(2009) K. Abduljalil et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Glutathione: A key player in autoimmunity

(2009) Carlo Perricone et al.   AUTOIMMUNITY REVIEWS

Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

(2009) ET Morgan   CLINICAL PHARMACOLOGY & THERAPEUTICS